NDC 67184-0530-1 - Bortezomib
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 67184-0530
- Requested NDC
- 67184-0530-1
- Package NDCs from labels
- 67184-0530-1
- Manufacturer
- Qilu Pharmaceutical Co., Ltd. | Qilu Pharmaceutical (Hainan) Co., Ltd.
- Effective date
- 2022-05-09
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Bortezomib | Qilu Pharmaceutical Co., Ltd. | Qilu Pharmaceutical (Hainan) Co., Ltd. | 2022-05-09 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 67184-0530-1 | Bortezomib | 1 in 1 CARTON | INJECTION, POWDER, LYOPHILIZED, | 1 | 1 | |
| 67184-0530-1 | Bortezomib | 1 in 1 VIAL | INJECTION, POWDER, LYOPHILIZED, | 1 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 67184-0530 | BORTEZOMIB INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [QILU PHARMACEUTICAL CO., LTD.] | 1 | Current NDC, Legacy NDC, 2 package rows | 20220510_aef02171-bf8a-43ad-b40c-7642623f9802.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| BORTEZOMIB | BORTEZOMIB | Apotex Corp | b605b541-4bfd-db3e-9710-11c27f6dee6c | 2026-09-09 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| Mannitol | MANNITOL | Hospira, Inc. | 8ad3145e-00e7-4412-b9a5-06f00f264f30 | 2026-04-21 | Warnings, Adverse reactions | 3OWL53L36A |
| Bortezomib | BORTEZOMIB | Avenacy, LLC | decb5d94-2ea2-48d8-b08b-3196b24c0ed3 | 2026-01-09 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Gland Pharma Limited | cd698074-da21-4b53-8f6b-241535a8d598 | 2026-01-08 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Ningbo Shuangcheng Pharmaceutical Co., Ltd. | b17ca681-59a5-4af7-98a4-953b38379893 | 2025-12-30 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| BORTEZOMIB | BORTEZOMIB | Eugia US LLC | ed526447-a4fe-403b-8f08-21ce1b2fa8b7 | 2025-12-23 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| Bortezomib | BORTEZOMIB | BluePoint Laboratories | 10f60367-0476-4acd-861b-90c18d4b8164 | 2025-11-20 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| QR PAIN | ANALGESIC | MARYHELENE ENTERPRISES INC | 8f8f53e3-fe31-e7b5-e053-2995a90a710d | 2025-11-14 | Warnings | 3OWL53L36A |
| QR PAIN | ANALGESIC | MARYHELENE ENTERPRISES INC | 9984a510-30be-4013-e053-2995a90a841e | 2025-11-14 | Warnings | 3OWL53L36A |
| Mannitol | MANNITOL | ProPharma Distribution | 430669d7-9ad1-9a04-e063-6394a90ababb | 2025-11-07 | Warnings, Adverse reactions | 3OWL53L36A |
| Sorbitol-Mannitol | SORBITOL AND MANNITOL | ICU Medical Inc. | 5b44e248-4b7b-4777-954a-921c7b309944 | 2025-10-30 | Warnings, Adverse reactions | 3OWL53L36A |
| Mannitol | MANNITOL | ICU Medical Inc. | ba7bf864-8a4d-4262-8fd1-00174fa2f9d1 | 2025-10-24 | Warnings, Adverse reactions | 3OWL53L36A |
| VELCADE | BORTEZOMIB | Takeda Pharmaceuticals America, Inc. | 1521d321-e724-4ffc-adad-34bf4f44fac7 | 2025-08-28 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| Osmitrol | MANNITOL | Baxter Healthcare Company | 0d914965-7001-45cb-ba51-d7c5964b05bc | 2025-08-26 | Warnings, Adverse reactions | 3OWL53L36A |
| Bortezomib | BORTEZOMIB | BluePoint Laboratories | c6b620c6-f3d6-4ff3-b46a-50a66e6d41dd | 2025-07-31 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Meitheal Pharmaceuticals Inc. | 322e315f-dd94-475f-94f4-4d86a7eb5590 | 2025-07-23 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| BORUZU | BORTEZOMIB | Amneal Pharmaceuticals LLC | b92628dd-fa09-4c3a-b6a3-66426025807c | 2025-07-05 | Warnings, Adverse reactions | 69G8BD63PP |
| Mannitol | MANNITOL | Henry Schein, Inc. | e2444db1-9dfe-451f-a33c-9b00786464d2 | 2025-05-20 | Warnings, Adverse reactions | 3OWL53L36A |
| Bortezomib | BORTEZOMIB | Somerset Therapeutics LLC | dc737d3d-2a4e-448a-ad70-e013065c411c | 2025-05-10 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| Bortezomib | BORTEZOMIB | NorthStar RxLLC | 3f02670b-5683-780c-9d38-5d8f0ef43a14 | 2025-05-06 | Warnings, Adverse reactions | 402243 69G8BD63PP |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.